Natural Killer T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Natural Killer T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy [Phase 2]
Phase 2 trial evaluating the combination of isatuximab and cemiplimab in relapsed or refractory Natural Killer/T-cell lymphoma has completed…
-
CLINICAL_TRIALS trial_result · 2026-01-05Clinical Trial Update: A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 study evaluating ATG-010 in combination with chemotherapy with maintenance ATG-010 in Peripheral T-cell lymphoma and natural kil…
-
CLINICAL_TRIALS trial_result · 2025-11-21Clinical Trial Update: A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) [Phase 2]
This Phase II study evaluates single-agent Brentuximab Vedotin in relapsed/refractory CD30-low mature T-cell lymphomas; the trial has comple…
-
CLINICAL_TRIALS trial_result · 2023-06-18Clinical Trial Update: PEG-ASP, Etoposide and Gemcitabine for Natural Killer/T Lymphoma [Phase 2]
Phase 2 clinical trial update for a regimen of PEG-ASP, etoposide, and gemcitabine for natural killer/T-cell lymphoma is reported, with the …
-
CLINICAL_TRIALS trial_result · 2022-06-09Clinical Trial Update: Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating a combination of sintilimab, peg-aspargase, and anlotinib for Natural Killer/T-Cell Lymphoma (nasal/nasal-type) h…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-09-14Clinical Trial Update: Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma [Phase 2]
Phase 2 trial evaluating anlotinib in advanced and refractory natural killer / T-cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2021-05-24Clinical Trial Update: Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma [Phase 2]
Phase 2 clinical trial update investigating dexamethasone, azacytidine, pegaspargase, and tislelizumab for NK/T cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-01-14Clinical Trial Update: A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type [Phase 2]
Phase 2 clinical trial assessing daratumumab for relapsed or refractory natural killer/T-cell lymphoma, nasal type; study completed with pos…
-
CLINICAL_TRIALS trial_result · 2020-01-28Clinical Trial Update: PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage [Phase 2]
Phase 2 trial comparing PEG-ASP+Gemoxd versus PEG-ASP+CHOP as first-line chemotherapy for early-stage NK/T-cell lymphoma; status and results…
-
CLINICAL_TRIALS trial_result · 2019-07-30Clinical Trial Update: PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma [Phase 4]
A Phase 4 clinical trial evaluating a combination of a PD-1 antibody, chidamide, lenalidomide, and etoposide for relapsed or refractory NK/T…
-
CLINICAL_TRIALS trial_result · 2017-01-20Clinical Trial Update: CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas [Phase 1]
Phase 1 study evaluating CHOP chemotherapy plus Campath-1H (alemtuzumab) as initial treatment for untreated aggressive T/NK-cell non-Hodgkin…
-
CLINICAL_TRIALS trial_result · 2010-09-08Clinical Trial Update: Study on the Combination Regimen of Dexamethasone Ifosfamide Cisplatin Etoposide in Patients With NK/T Cell Lymphoma [Phase 2]
This document provides an update on a Phase 2 clinical trial evaluating a dexamethasone–ifosfamide–cisplatin–etoposide regimen in natural ki…
-
CLINICAL_TRIALS trial_result · 2009-10-14Clinical Trial Update: Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas [Phase 1, Phase 2]
A completed Phase 1/2 clinical study evaluated combining bortezomib with CHOP chemotherapy in patients with advanced aggressive T-cell lymph…